August 29, 2017 / eMedClub / -- After Novartis' CAR-T therapy was unanimously approved by the U.S. FDA Oncology Drug Expert Advisory Committee, the world's attention was once again cast on the most epoch-making cancer treatment drug - CAR-T cells. The two leading companies, Novartis and Kite, have long been ready to welcome the launch of the first CAR-T drug.
With the successful application of CAR-T in relapsed and refractory leukemia and lymphoma, innovative cell therapies represented by CAR-T and TCR are increasingly becoming the focus of attention in the global pharmaceutical and health industry. 2017 is an extraordinary year, with many technological breakthroughs and clinical progress promoting the rapid development of the industry. On the eve of the launch of CAR-T therapy, the 2017 Third CAR-TCR Global Summit will be grandly opened in Boston, USA from September 5th to 8th. The CAR-TCR Global Summit has been successfully held twice before and has been highly valued by global cell therapy peers. The scale and specifications of this conference are the largest ever. More than 500 corporate executives and senior researchers from more than 60 industry experts, more than 200 biopharmaceutical companies and research institutions from around the world will gather in Boston. In more than 90 theme activities over 4 days, experts will conduct in-depth discussions on topics such as the research progress, clinical transformation, cell production and future commercialization of CAR-T and TCR therapies, and jointly perform a peak event in the field of cell therapy. The 2017 CAR-TCR Global Summit attracted many cell therapy companies from around the world to participate, and all well-known leading companies in the industry were present. Novartis, Kite, and Juno are recognized as the three major players in CAR-T therapy in the industry. Bluebird, Cellectics , Adaptimmune , Ziopharm Oncology and other industry upstarts have come from behind, and major pharmaceutical companies that focus on cell therapy, such as Pfizer, Merck, Roche, GSK, and Eli Lilly, have sent executives to attend this conference. This summit will also bring another highlight. China's representative companies, Stansay Biopharmaceuticals and Coherus Biopharmaceuticals, have also been invited to attend the conference and report to global cell therapy peers on the current status of clinical applications of CAR-T cells in China. Let us wait and see whether Chinese scientists can bring out the strongest national style in Boston.